2. Metabolic Enzyme/Protease Apoptosis
  3. Dihydroorotate Dehydrogenase Apoptosis
  4. MEDS700

MEDS700 is a blood-brain barrier permeable inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 1.5 nM. MEDS700 induces apoptosis and differentiation, and inhibits proliferation of cancer cells. MEDS700 can be used in research on acute myeloid leukemia and other conditions.

For research use only. We do not sell to patients.

MEDS700

MEDS700 Chemical Structure

CAS No. : 2770979-81-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

MEDS700 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MEDS700 is a blood-brain barrier permeable inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 1.5 nM. MEDS700 induces apoptosis and differentiation, and inhibits proliferation of cancer cells. MEDS700 can be used in research on acute myeloid leukemia and other conditions[1].

In Vitro

MEDS700 (0.001-10 μM; 3 days) induces differentiation and apoptosis in THP1 and U937 acute myeloid leukemia (AML) cell lines, with an EC50 value ranging from 19 nM to 64 nM[1].
MEDS700 (0.1-1 μM; 3 days) induces apoptosis in MV4-11 acute myeloid leukemia (AML) cells at concentrations of 0.1 μM and 1 μM[1].
MEDS700 exhibits potent antiproliferative activity against a panel of solid tumor cell lines at nanomolar concentrations, with the strongest activity observed in neuroblastoma, Ewing sarcoma, bladder cancer and fibrosarcoma cells[1].
MEDS700 potently inhibits the proliferation of SF7761 and SU-DIPG-XIII DMG cell lines, with EC50 values of 9.3 nM and 32.9 nM, respectively, and exhibits activity in SF8628 cells with extended exposure time[1].
MEDS700 (72 h) exerts antiproliferative and cytotoxic effects on SH-SY5Y neuroblastoma cells via pyrimidine depletion, induces S-phase cell cycle arrest, caspase-dependent apoptosis, and irreversible loss of colony-forming ability, with an EC50 of 13 nM[1].
MEDS700 (1-100 μM; 72 h) exhibits only extremely low toxicity in mixed neural cell cultures derived from human induced pluripotent stem cells (hiPSCs), with an EC30 of 199 μM, indicating that this compound has a favorable safety window relative to its anti-tumor activity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MEDS700 Related Antibodies

Apoptosis Analysis[1]

Cell Line: MV4-11 AML cells
Concentration: 0.1 μM, 1 μM
Incubation Time: 3 days
Result: Induced ~40% apoptosis at both 0.1 μM and 1 μM.
Co-treatment with 5 μM uridine reduced apoptosis.
Co-treatment with dipyridamole (1.0 μM) increased apoptosis to ~100% at both concentrations, even in the presence of 5 μM or 100 μM uridine.
Parmacokinetics
Species Dose Route T1/2 Bioavailability Cmax Brain Concentration Tmax C0 AUC0-∞
Mice[1] 5 mg/kg i.v. 8.1 h / 66.35 h / 0.25 h 74.45 μg/mL 435.10 μg/mL·h
Mice[1] 20 mg/kg p.o. >12 h 37.8 % 0.67 μg/mL ~160 nM / / /
In Vivo

MEDS700 (5-20 mg/kg; i.v., p.o.; single dose) demonstrates favorable oral bioavailability, sustained systemic exposure, and effective BBB penetration, maintaining brain concentrations above its in vitro anticancer EC50 range for 24 hours after oral administration[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Balb/c (male, 8 weeks old)[1]
Dosage: 5 mg/kg (i.v.); 20 mg/kg (p.o.)
Administration: i.v.; single dose; p.o.; single dose
Result: Exhibited oral bioavailability of 37.8%.
Showed a half-life of over 12 hours after oral administration and 8.1 hours after intravenous administration.
Reached an intracerebral Cmax of 0.67 μg/mL.
Maintained a therapeutically relevant brain concentration of approximately 160 nM for up to 24 hours after oral administration.
Molecular Weight

495.37

Formula

C23H15F6N3O3
CAS No.
SMILES

FC1=C(F)C(NC(C2=C3C=CC=CN3N=C2O)=O)=C(F)C(F)=C1C4=CC(OCC(F)(F)C)=CC=C4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

MEDS700 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MEDS7002770979-81-0MEDS 700MEDS-700Dihydroorotate DehydrogenaseApoptosisDHODHneuroblastomaArg136Gln47hDHODHde novo pyrimidine biosynthesisTyr38human dihydroorotate dehydrogenaseacute myeloid leukemiaglioblastomadiffuse midline gliomasInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MEDS700
Cat. No.:
HY-183336
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.